Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The goal of this multi-center Phase II study is to add bortezomib to the highly active
regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a
weekly schedule (Days 1, 8, 15) and will be added to bendamustine/rituximab given in 4-week
cycles. This combination uses the standard bendamustine dosing schedule, and is more
convenient than the 5-week regimen of these 3 drugs currently being studied.